Unbiased screening of protein and/or peptide levels in CSF, in relation to changes of the traditional Aβ and tau biomarkers in a clinically diverse cohort, could help identify distinct markers related to glucose metabolism that are altered in AD as opposed to other neurological processes. Here, MAPT is linked to Alzheimer disease.